Holen Sie sich die Stockscreener-App
501.19
0.29%
1.43
Handel nachbörslich:
501.19
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$499.76
Offen:
$505.34
24-Stunden-Volumen:
319.88K
Relative Volume:
1.03
Marktkapitalisierung:
$11.56B
Einnahmen:
$1.13B
Nettoeinkommen (Verlust:
$-309.44M
KGV:
-39.16
EPS:
-12.8001
Netto-Cashflow:
$-275.41M
1W Leistung:
+5.10%
1M Leistung:
-4.30%
6M Leistung:
-9.63%
1J Leistung:
+75.82%
1-Tages-Spanne:
$493.00
$507.75
1-Wochen-Bereich:
$460.89
$507.75
52-Wochen-Spanne:
$275.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
501.19 | 11.52B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Globe and Mail
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Madrigal (MDGL) down 7.9% since last earnings report: Can it rebound? - MSN
MDGL Maintained by B of A Securities -- Price Target Lowered to $542 - GuruFocus
BofA cuts Madrigal Pharmaceuticals price target on competition concerns By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals launches 'MASH Across America' with giant inflatable liver in Philly - PharmaLive
MDGL: Rezdiffra’s blockbuster launch and expanding pipeline position the company for sustained growth - TradingView
Madrigal Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Madrigal Investors Focus on Rezdiffra Growth at Goldman Event - MyChesCo
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Exploring A 39% Upside Potential - DirectorsTalk Interviews
Goldman Sachs Group Inc. Trims Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Fiera Capital Corp Acquires 41,656 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Return on invested capital % of Madrigal Pharmaceuticals, Inc. – XETR:YDO1 - TradingView
Madrigal Pharmaceuticals, Inc. News — XETR:YDO1 - TradingView
Madrigal Pharmaceuticals, Inc. Statistics – XETR:YDO1 - TradingView
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Madrigal Q1 2026 slides: blockbuster Rezdiffra tops $1.1B in sales - Investing.com
(MDGL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Earnings call transcript: Madrigal Pharmaceuticals Q1 2026 surprises with earnings beat - Investing.com
Legal & General Group Plc Sells 6,440 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal (MDGL) Data Highlights Rezdiffra’s Cardiometabolic Benefits for MASH Patients at EASL Congress - Insider Monkey
Madrigal Highlights Rezdiffra Data as MASH Market Expands - MyChesCo
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 - The Manila Times
12 Best High Short Interest Stocks With Highest Upside Potential - Insider Monkey
Geode Capital Management LLC Has $263.11 Million Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals targets liver disease with Rezdiffra, eyeing strong growth despite competition risks. - Pluang
Madrigal Pharmaceuticals Could Become The Next Vertex - Seeking Alpha
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness - Yahoo Finance
Madrigal Pharmaceuticals (MDGL) slides as insider sale headlines hit and investors take profits - Quiver Quantitative
Insider Sell: David Soergel Sells Shares of Madrigal Pharmaceuti - GuruFocus
Madrigal Pharmaceuticals CMO David Soergel sells $516,561 in shares By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals CMO David Soergel sells $516,561 in shares - Investing.com
Madrigal (MDGL) CMO sells 1,042 shares in 10b5-1 trade, holds 10,033 - Stock Titan
MDGL (NASDAQ) insider files Form 144 reporting sale of 1,042 shares - Stock Titan
Citizens reiterates Madrigal Pharmaceuticals stock rating on liver data By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals, Inc. (MDGL): Investor Outlook Reveals 35.71% Potential Upside - DirectorsTalk Interviews
Has Madrigal Pharmaceuticals (MDGL) Cracked the Code for MASH - Kavout
H.C. Wainwright Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $620 - Moomoo
Madrigal Expands Workforce With Equity Hiring Grants - MyChesCo
Madrigal Pharmaceuticals (MDGL) Reports Positive Findings on Rez - GuruFocus
Madrigal Pharmaceuticals Says Data Show Rezdiffra Reduces Cardiovascular, Liver-Related Risks in MASH Patients - Moomoo
Madrigal Pharmaceuticals (MDGL) Reports Positive Findings on Rezdiffra for MASH Treatment - GuruFocus
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH - The Manila Times
Madrigal Presents Data Demonstrating Rezdiffra Reduced - GlobeNewswire
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,928,716, According to a Recent SEC Filing - Moomoo
(MDGL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 30% Upside Beckons in the Biotech Sector - DirectorsTalk Interviews
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):